Jonathan C. Javitt, MD, MPH
Johns Hopkins University
H-index: 70
North America-United States
Top articles of Jonathan C. Javitt, MD, MPH
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
NRX-101 (D-Cycloserine+ Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro | Antibiotics | Michael T Sapko Michael Manyak Riccardo Panicucci Jonathan C Javitt | 2024/3/28 |
NRX-101 (D-Cycloserine+ Lurasidone), a Qualified Infectious Disease Product, is Active Against Drug-Resistant Urinary Pathogens In Vitro | bioRxiv | Michael Todd Sapko Michael Manyak Riccardo Panicucci Jonathan C Javitt | 2024 |
NRX-101, a Rapid-Acting Anti-Depressant, Does Not Cause Neurotoxicity Following Ketamine Administration in Preclinical Models | International Journal of Toxicology | William Jordan Michael T Sapko Richard Siegel Jonathan Javitt | 2023/10 |
Potential Value of the Radiographic Assessment of Lung Edema (RALE) Score to Assess Resolution of Pulmonary Edema in a Clinical Trial in ARDS | M Jabaudon M Warren T Koyama P Lavin J Javitt | 2023/5 | |
D-Cycloserine for the Treatment of Chronic Pain | Authorea Preprints | Jonathan C Javitt Michael T Sapko | 2023/8/14 |
International Journal of Bipolar Disorders | Andrew Nierenberg Philip Lavin Daniel C Javitt Richard Shelton Michael T Sapko | 2023 | |
NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute … | International journal of bipolar disorders | Andrew Nierenberg Philip Lavin Daniel C Javitt Richard Shelton Michael T Sapko | 2023/8/13 |
Andrew Nierenberg1, Philip Lavin2, Daniel C. Javitt3, 4, Richard Shelton5, Michael T. Sapko4, Sanjay Mathew6 | Robert E Besthof Jonathan C Javitt | 2023 | |
Real Time Quality Assurance of Depression Ratings in Psychiatric Clinical Trials | Available at SSRN 4537055 | Marc Korczykowski Michael Sapko Courtney Colesare Ian Sharpe Philip Lavin | 2023/8/10 |
D-cycloserine is not susceptible to self-administration using an intravenous self-administration model in male ketamine-habituated Sprague-Dawley rats | Pharmacology Biochemistry and Behavior | Michael T Sapko Taleen Hanania Qing Chang Jonathan C Javitt | 2023/6/1 |
D-cycloserine (DCS) is Not Susceptible to Self-administration, unlike S-ketamine Using an Intravenous Self-administration Model in Naive and Ketamine-habituated Sprague-Dawley Rats | bioRxiv | Daniel C Javitt Jonathan C Javitt | 2022/8/15 |
Brief report: rapid clinical recovery from critical coronavirus disease 2019 with respiratory failure in a pregnant patient treated with IV vasoactive intestinal peptide | Critical care explorations | Jihad Georges Youssef Mohammad Z Bitar Faisal Zahiruddin Mukhtar Al-Saadi Mahmoud Elshawwaf | 2022/1/1 |
The use of IV vasoactive intestinal peptide (aviptadil) in patients with critical COVID-19 respiratory failure: results of a 60-day randomized controlled trial | Critical care medicine | Jihad Georges Youssef Philip Lavin David A Schoenfeld Richard A Lee Rainer Lenhardt | 2022/11/1 |
Handheld blood glucose monitoring device with messaging capability | 2022/8/16 | ||
Effectiveness of ZYESAMI™(Aviptadil) in Accelerating Recovery and Shortening Hospitalization in Critically-Ill Patients with COVID-19 Respiratory Failure: Interim Report from … | Jihad G Youssef Richard Lee Jonathan Javitt Philip Lavin Dushyantha Jayaweera | 2021/4/1 | |
Rapid clinical recovery from critical COVID-19 pneumonia with vasoactive intestinal peptide treatment | The Journal of Heart and Lung Transplantation | S Beshay JG Youssef F Zahiruddin M Al-Saadi S Yau | 2021/4/1 |
Treatment of Acute Respiratory Distress Syndrome with Vasoactive Intestinal Peptide | Matthew J Javitt Jonathan C Javitt | 2021/9/29 | |
Intravenous aviptadil is associated with increased recovery and survival in patients with COVID-19 respiratory failure: results of a 60-day randomized controlled trial | Available at SSRN 3830051 | Jihad G Youssef Richard Lee Jonathan Javitt Philip Lavin Rainer Lenhardt | 2021/8/7 |
VIP in the Treatment of Critical COVID-19 Respiratory Failure in Patients with Severe Comorbidities | JG Youssef J Javitt P Lavin M Al-Saadi F Zahiruddin | 2021/5 | |
Vasoactive intestinal peptide treats respiratory failure in COVID-19 by rescuing the alveolar type II cell | Authorea Preprints | Jonathan C Javitt | 2020/7/25 |
Co-Authors
